Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

WIN-55,212-2

Cannabinoid receptor agonist
 
BML-CR105-0010 10 mg 89.00 USD
 
BML-CR105-0050 50 mg 390.00 USD
Do you need bulk/larger quantities?
 
Replaces Prod. #: ALX-270-243

High affinity cannabinoid receptor (CB) agonist (Ki=62.3nM and 3.3nM at the human cloned CB1 and CB2 receptors, respectively). Potent analgesic in a rat model of neuropathic pain. Activates p42 and p44 MAP kinase via a receptor-mediated signaling.

Product Specification

Alternative Name:(R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone . mesylate
 
Formula:C27H26N2O3 . CH3SO3H
 
MW:522.6
 
CAS:131543-23-2
 
Purity:≥98% (HPLC)
 
Appearance:White to off-white solid.
 
Solubility:Soluble in DMSO; insoluble in water.
 
Shipping:Ambient
 
Long Term Storage:+4°C
 
Use/Stability:Stable for at least 1 year after receipt when stored, as supplied, at 0-4°C. Stock solutions are stable for up to 3 months at -20°C.
 
Technical Info/Product Notes:WIN-55,212-2 is a controlled substance in some countries and may require an import/export license from the local authorities depending on the country of import. Orders for this product will incur an administrative fee to cover license expenses. Please inquire for additional information.
 
Regulatory Status:RUO - Research Use Only
 
bml-cr105
Please mouse over
bml-cr105

Product Literature References

Cannabinoid functions in the amygdala contribute to conditioned fear memory in streptozotocin-induced diabetic mice: Interaction with glutamatergic functions: H. Ikeda, et al.; Exp. Neurol. 269, 233 (2015), Application(s): Injection into mice, Abstract;
Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212: J.L. Croxford & S.D. Miller ; J. Clin. Invest. 111, 1231 (2003), Abstract;
Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation: I. Galve-Roperh, et al.; Nat. Med. 6, 313 (2000), Abstract;
An analgesia circuit activated by cannabinoids: I.D. Meng, et al.; Nature 395, 6700 (1998), Abstract;
The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain: U. Herzberg, et al.; Neurosci. Lett. 221, 157 (1997), Abstract;
Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system: X. Pan, et al.; Mol. Pharmacol. 49, 707 (1996), Abstract;
Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1: M. Bouaboula, et al.; Biochem. J. 312, 637 (1995), Abstract;
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors: C.C. Felder, et al.; Mol. Pharmacol. 48, 443 (1995), Abstract;
Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors: J.P. Terranova, et al.; Naunyn-Schmiedeberg's Arch. Pharmacol. 352, 576 (1995), Abstract;
(+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters: A. Richter & W. Loscher; Eur. J. Pharmacol. 264, 371 (1994), Abstract;
Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor: T.E. D'Ambra, et al.; J. Med. Chem. 35, 124 (1992), Abstract;

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
Cannabinoid receptor
MAPK
By biological activity:
Cannabinoid receptor Ligand
MAPK Activator
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Related Literature

Brochures
Essential Research Tools for Neurodegeneration & Neural Signaling
Essential Research Tools for Neurodegeneration & Neural Signaling
Download as PDF

All new literature pieces

Recommend this page

 
Keep in touch

©2020 Enzo Life Sciences, Inc.,